La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tus-Pharmaceutical Group Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Xue Feng

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.3yrs
Proprietà del CEO	n/a
Durata media del management	4.3yrs
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals

Apr 03

Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%

Mar 08

AMMINISTRATORE DELEGATO

Xue Feng (34 yo)

4.3yrs

Mandato

CN¥420,000

Compensazione

Mr. Xue Feng serves as the Non Independent Director of Tus-Pharmaceutical Group Co., Ltd. (formerly known as Tus-Guhan Group Corp.,Ltd.) since May 21, 2020 and serves as its President.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ting Tang	VP, CFO & Non Independent Director	7.7yrs	CN¥370.00k	Nessun dato
Dingxing Cao	VP & Board Secretary	no data	CN¥370.00k	Nessun dato
Jun Cai	Vice President	1.3yrs	CN¥345.00k	Nessun dato
Xue Feng	President & Non Independent Director	4.3yrs	CN¥420.00k	Nessun dato

4.3yrs

Durata media

44yo

Età media

Gestione esperta: Il team dirigenziale di 000590 è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ting Tang	VP, CFO & Non Independent Director	7.7yrs	CN¥370.00k	Nessun dato
Xue Feng	President & Non Independent Director	4.3yrs	CN¥420.00k	Nessun dato
Kebiao Yan	Chairman of the Board of Supervisors	7.2yrs	Nessun dato	Nessun dato
Qisen Jiao	Chairman of the Board	3.8yrs	CN¥420.00k	Nessun dato
Zhengming Huang	Independent Director	3.7yrs	CN¥120.00k	Nessun dato
Jingwei Sun	Supervisor	3.7yrs	Nessun dato	Nessun dato
Xiaoqiao Ni	Vice Chairman	1.3yrs	Nessun dato	Nessun dato
Zhenhua Lei	Independent Director	1.3yrs	CN¥70.00k	Nessun dato
Wenbiao Huang	Independent Director	1.3yrs	Nessun dato	Nessun dato

3.7yrs

Durata media

50yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 000590 sono considerati esperti (durata media dell'incarico 3.7 anni).

Tus-Pharmaceutical Group Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 28, 2024

High number of new and inexperienced directors

Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments

High number of new directors

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Recent updates

Tus-Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 28, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: CN¥0.035 loss per share (vs CN¥0.028 profit in 1Q 2023)

Investor sentiment deteriorates as stock falls 26%

Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals

Tus-Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.076 in FY 2022)

Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%

New minor risk - Share price stability

Tus-Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.017 in 3Q 2022)

Tus-Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.004 loss in 2Q 2022)

Tus-Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

High number of new and inexperienced directors

Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments

Full year 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.15 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.017 (vs CN¥0.041 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.004 loss per share (vs CN¥0.036 profit in 2Q 2021)

Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.085 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.095 in FY 2020)

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.023 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.021 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.037 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.095 (vs CN¥0.18 in FY 2019)

Tus-Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥7.77

New 90-day low: CN¥8.29

New 90-day low: CN¥9.42

Tus-Guhan Group Corp.,Ltd. Approves Board Elections

New 90-day low: CN¥9.45

Tus-Guhan Group Corp.,Ltd. Approves Election of Jiao Qisen as A Non-Independent Director

New 90-day low: CN¥9.55

New 90-day low: CN¥9.84

New 90-day high - CN¥12.57

Tus-Guhan Group Corp.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media